1 Y, Z. et al. Clinicopathologic features and prognostic factors in patients with renal cell carcinoma with sarcomatoid differentiation. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica, doi:10.1111/apm.13035 (2020).
2 S, G. & U, V. Current State of Systemic Therapies for Advanced Renal Cell Carcinoma. Current oncology reports 22, 26, doi:10.1007/s11912-020-0892-1 (2020).
3 W, X., MB, A. & DF, M. Checkpoint inhibitor immunotherapy in kidney cancer. Nature reviews. Urology, doi:10.1038/s41585-020-0282-3 (2020).
4 AW, H. et al. A Phase I Study of Alpha-1,3-Galactosyltransferase-Expressing Allogeneic Renal Cell Carcinoma Immunotherapy in Patients with Refractory Metastatic Renal Cell Carcinoma. The oncologist 25, 121-e213, doi:10.1634/theoncologist.2019-0599 (2020).
5 JE, S. et al. Pan-Tumor Pathologic Scoring of Response to PD-(L)1 Blockade. Clinical cancer research : an official journal of the American Association for Cancer Research 26, 545-551, doi:10.1158/1078-0432.ccr-19-2379 (2020).
6 L, F. et al. Mechanisms of resistance to mTOR inhibitors. Critical reviews in oncology/hematology 147, 102886, doi:10.1016/j.critrevonc.2020.102886 (2020).
7 RA, F. et al. Results of the ADAPT phase 3 study of Rocapuldencel-T in combination with sunitinib as first-line therapy in patients with metastatic renal cell carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research, doi:10.1158/1078-0432.ccr-19-2427 (2020).
8 C, D. et al. Tissues in different anatomical sites can sculpt and vary the tumor microenvironment to affect responses to therapy. Molecular therapy : the journal of the American Society of Gene Therapy 22, 18-27, doi:10.1038/mt.2013.219 (2014).
9 S, L. & W, X. Mining TCGA database for screening and identification of hub genes in kidney renal clear cell carcinoma microenvironment. Journal of cellular biochemistry, doi:10.1002/jcb.29511 (2019).
10 G, L. et al. LncRNA TP73-AS1 Promotes Cell Proliferation and Inhibits Cell Apoptosis in Clear Cell Renal Cell Carcinoma Through Repressing KISS1 Expression and Inactivation of PI3K/Akt/mTOR Signaling Pathway. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 48, 371-384, doi:10.1159/000491767 (2018).
11 G, W. et al. Novel long noncoding RNA OTUD6B-AS1 indicates poor prognosis and inhibits clear cell renal cell carcinoma proliferation via the Wnt/β-catenin signaling pathway. Molecular cancer 18, 15, doi:10.1186/s12943-019-0942-1 (2019).
12 J, S. et al. Identification and Validation of Two Novel Prognostic lncRNAs in Kidney Renal Clear Cell Carcinoma. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 48, 2549-2562, doi:10.1159/000492699 (2018).
13 MJ, H. et al. HOTAIRM1 lncRNA is downregulated in clear cell renal cell carcinoma and inhibits the hypoxia pathway. Cancer letters 472, 50-58, doi:10.1016/j.canlet.2019.12.022 (2020).
14 X, P., X, W. & H, L. LncRNA SNHG1 regulates the differentiation of Treg cells and affects the immune escape of breast cancer via regulating miR-448/IDO. International journal of biological macromolecules 118, 24-30, doi:10.1016/j.ijbiomac.2018.06.033 (2018).
15 D, H. et al. NKILA lncRNA promotes tumor immune evasion by sensitizing T cells to activation-induced cell death. Nature immunology 19, 1112-1125, doi:10.1038/s41590-018-0207-y (2018).
16 H, Z. et al. Long noncoding RNA lnc-DILC stabilizes PTEN and suppresses clear cell renal cell carcinoma progression. Cell & bioscience 9, 81, doi:10.1186/s13578-019-0345-4 (2019).
17 J, E. et al. The long non-coding RNA lnc-ZNF180-2 is a prognostic biomarker in patients with clear cell renal cell carcinoma. American journal of cancer research 5, 2799-2807, doi:undefined (2015).
18 H, Z., C, L. & G, Z. MCM3AP-AS1LncRNA Regulates Epidermal Growth Factor Receptor and Autophagy to Promote Hepatocellular Carcinoma Metastasis by Interacting with. DNA and cell biology 38, 857-864, doi:10.1089/dna.2019.4770 (2019).
19 DJ, C. et al. Integrated Proteogenomic Characterization of Clear Cell Renal Cell Carcinoma. Cell 179, 964-983.e931, doi:10.1016/j.cell.2019.10.007 (2019).
20 L, P. et al. EVI1 as a Prognostic and Predictive Biomarker of Clear Cell Renal Cell Carcinoma. Cancers 12, doi:10.3390/cancers12020300 (2020).
21 T, T. et al. Predictive factors for recurrence after partial nephrectomy for clinical T1 renal cell carcinoma: a retrospective study of 1227 cases from a single institution. International journal of clinical oncology, doi:10.1007/s10147-020-01632-x (2020).
22 T, W. et al. An Empirical Approach Leveraging Tumorgrafts to Dissect the Tumor Microenvironment in Renal Cell Carcinoma Identifies Missing Link to Prognostic Inflammatory Factors. Cancer discovery 8, 1142-1155, doi:10.1158/2159-8290.cd-17-1246 (2018).
23 B, B. et al. Pro-angiogenic gene expression is associated with better outcome on sunitinib in metastatic clear-cell renal cell carcinoma. Acta oncologica (Stockholm, Sweden) 57, 498-508, doi:10.1080/0284186x.2017.1388927 (2018).
24 L, Q. et al. Prognostic Value of a Long Non-coding RNA Signature in Localized Clear Cell Renal Cell Carcinoma. European urology 74, 756-763, doi:10.1016/j.eururo.2018.07.032 (2018).
25 W, Z. et al. A positive feed-forward loop between LncRNA-URRCC and EGFL7/P-AKT/FOXO3 signaling promotes proliferation and metastasis of clear cell renal cell carcinoma. Molecular cancer 18, 81, doi:10.1186/s12943-019-0998-y (2019).
26 S, K. et al. Immune associated LncRNAs identify novel prognostic subtypes of renal clear cell carcinoma. Molecular carcinogenesis 58, 544-553, doi:10.1002/mc.22949 (2019).
27 W, W. et al. Long non-coding RNA UCA1 promotes malignant phenotypes of renal cancer cells by modulating the miR-182-5p/DLL4 axis as a ceRNA. Molecular cancer 19, 18, doi:10.1186/s12943-020-1132-x (2020).
28 C, W. et al. Bioinformatics profiling utilized a nine immune-related long noncoding RNA signature as a prognostic target for pancreatic cancer. Journal of cellular biochemistry 120, 14916-14927, doi:10.1002/jcb.28754 (2019).
29 M, Z. et al. An Immune-Related Six-lncRNA Signature to Improve Prognosis Prediction of Glioblastoma Multiforme. Molecular neurobiology 55, 3684-3697, doi:10.1007/s12035-017-0572-9 (2018).